blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2237684

EP2237684 - AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.03.2017
Database last updated on 02.11.2024
FormerGrant of patent is intended
Status updated on  29.11.2016
Most recent event   Tooltip17.03.2017Application deemed to be withdrawnpublished on 19.04.2017  [2017/16]
Applicant(s)For all designated states
Akthelia Pharmaceuticals
Frostaskjol 89
107 Reykjavik / IS
[2011/13]
Former [2011/11]For all designated states
Akthelia Pharmaceuticals
Frostaskjol 89
107 Reykavjik / IS
Former [2010/41]For all designated states
Akthelia Pharmaceuticals
Brekkugerdi 28
108 Reykjavik / IS
Inventor(s)01 / GUDMUNDSSON, Gudmundur, Hrafn
Professor of Cell Biology Biology Institute University of Iceland Sturlugata 7
IS-101 Reykjavik / IS
02 / AGERBERTH, Birgitta
Department of Medical Biochemistry and Biophysics Karolinska Institutet
S-171 77 Stockholm / SE
03 / STEINGRIMSSON, Eirikur
Department of Biochemistry and Molecular Biology Faculty of Medicine University of Iceland Vatnsmyrarvegur 16
IS-101 Reykjavik / IS
04 / STROMBERG, Roger
Karolinska Institutet Department of Biosciences and Nutrition Novum
S-141 57 Huddinge / SE
05 / RAQIB, Rubhana
International Centre for Diarrhoeal Disease Research Bangladesh (ICDDRB) GPO Box 128
Dhaka 1000 / BD
 [2010/41]
Representative(s)Kremer, Simon Mark, et al
Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2010/41]Kremer, Simon Mark, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date08869882.411.12.2008
[2010/41]
WO2008IB03709
Priority number, dateUS20080019652P08.01.2008         Original published format: US 19652 P
[2010/41]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009087474
Date:16.07.2009
Language:EN
[2009/29]
Type: A2 Application without search report 
No.:EP2237684
Date:13.10.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 16.07.2009 takes the place of the publication of the European patent application.
[2010/41]
Search report(s)International search report - published on:EP03.09.2009
ClassificationIPC:A61P31/04, A61P31/10, A61K31/192, A61K31/198, A61K45/06, A61P31/12, A61P33/06
[2016/26]
CPC:
A61K31/192 (EP,US); A23L33/10 (EP,US); A61K31/198 (EP,US);
A61K45/06 (EP,US); A61P1/00 (EP); A61P1/04 (EP);
A61P1/12 (EP); A61P11/00 (EP); A61P11/02 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P17/00 (EP);
A61P27/02 (EP); A61P31/04 (EP); A61P31/10 (EP);
A61P31/12 (EP); A61P31/16 (EP); A61P33/06 (EP);
A61P43/00 (EP); Y02A50/30 (EP,US) (-)
Former IPC [2010/41]A23L1/30, A61K31/192, A61K31/198, A61K45/06, A61P31/04, A61P31/10, A61P31/12, A61P33/06
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/41]
TitleGerman:AGONISTEN FÜR ANTIMIKROBIELLE PEPTIDSYSTEME[2010/41]
English:AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS[2010/41]
French:AGONISTES POUR DES SYSTÈMES PEPTIDIQUES ANTIMICROBIENS[2010/41]
Entry into regional phase27.07.2010National basic fee paid 
27.07.2010Designation fee(s) paid 
20.07.2010Examination fee paid 
Examination procedure09.11.2009Request for preliminary examination filed
International Preliminary Examining Authority: EP
20.07.2010Amendment by applicant (claims and/or description)
20.07.2010Examination requested  [2010/41]
21.11.2011Despatch of a communication from the examining division (Time limit: M04)
16.03.2012Reply to a communication from the examining division
11.12.2012Despatch of a communication from the examining division (Time limit: M06)
09.10.2013Reply to a communication from the examining division
23.10.2014Despatch of a communication from the examining division (Time limit: M06)
24.07.2015Reply to a communication from the examining division
25.05.2016Cancellation of oral proceeding that was planned for 21.06.2016
14.06.2016Communication of intention to grant the patent
21.06.2016Date of oral proceedings (cancelled)
25.10.2016Application deemed to be withdrawn, date of legal effect  [2017/16]
30.11.2016Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2017/16]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.11.2011
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
24.07.2015Request for further processing filed
24.07.2015Full payment received (date of receipt of payment)
Request granted
05.08.2015Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
09.10.2013Request for further processing filed
09.10.2013Full payment received (date of receipt of payment)
Request granted
23.10.2013Decision despatched
Fees paidRenewal fee
21.12.2010Renewal fee patent year 03
20.12.2011Renewal fee patent year 04
20.12.2012Renewal fee patent year 05
19.12.2013Renewal fee patent year 06
22.12.2014Renewal fee patent year 07
22.12.2015Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.12.201609   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US2007021508  (YEN RONG-LANG [TW], et al) [X] 1-4,6,7,9,12-14,17,18,20-25,27,28,30-33 * claims 1,7-16 * * page 2, paragraph 14 * * page 4, paragraph 34 *;
 [X]US2006045912  (TRUOG PETER [CH]) [X] 1-7,9,12-14,17-21,23-26,28-33 * claims 24,25,33,34,44,45,51,52 * * page 18, paragraphs 180,186 * * page 19, paragraph 192 * * page 22, paragraphs 217,218 * * page 28, paragraph 278; example 1 *;
 [X]US5635533  (SAMID DVORIT [US]) [X] 1-4,6,7,9,12-14,17,18,21-28,30,31,33 * column 6, line 17 - column 7, line 5 * * column 7, lines 55-57 * * column 42, line 20 - column 44, line 4 * * column 57, lines 9-24 * * column 66, lines 14-17 * * column 66, lines 39-41 * * columns 67,68 *;
 [X]WO9804290  (PERRINE SUSAN P [US], et al) [X] 1-4,6,7,9,12-14,17,18,21-23,27,28,30,33 * page 24, lines 8-11 * * page 43, line 17 - page 44, line 1 * * page 54, line 19 * * claims 1,7 *;
 [X]WO9840078  (BEACON LAB L L C [US]) [X] 1-4,6,7,9,12-14,17,18,21-28,30-33 * claims 45,46,81,82 * * page 19, lines 5-9 * * page 10, line 35 - page 11, line 10 * * page 30, line 29 - page 31, line 4 * * page 30, lines 22-27 *;
 [X]DE102006026464  (VIROLOGIK GMBH INNOVATIONSZENT [DE]) [X] 1-4,6,7,9,12-14,17,18,21,23,30,33 * claims 4,6,18,31 * * page 2, paragraph 1 *;
 [X]WO0238181  (SCHUER JOERG P [DE]) [X] 1,2,4,9,12-14,17,18,21,23-25,28,30,31,33 * page 5, paragraph 8; claims 1,2,40,42 *;
 [X]WO2004091307  (ADVANCED BIONUTRITON CORP [US], et al) [X] 1,2,4,9,12-14,17-25,27-31 * page 6, paragraph 36 * * page 7, paragraphs 38,39 * * page 11, paragraphs 65,67,68 * * claims 1,3,9,23 *;
 [X]US6011000  (PERRINE SUSAN P [US], et al) [X] 1,2,4,9,12-14,17,18,20,21,23-25,28,30,31,33 * claims 4,5,10 * * column 19, lines 3-25 * * column 20, lines 31,48-63 * * column 23, line 59 - column 24, line 11 * * column 26, lines 26-31 *;
 [X]DE19518262  (HOECHST AG [DE]) [X] 1,2,5,6,9,10,14,18,21,23,30,33 * claim 1 *;
 [X]US2004091506  (BOMMARITO ALEXANDER A [US]) [X] 1-3,5,6,9,10,14,18,20-23,27,30,33 * page 2, paragraph 15; claims 1,9,12 *;
 [X]WO03105826  (CRISTALIA PROD QUIMICOS FARM [BR], et al) [X] 1-3,5,6,9,10,14,18,21,23-25,28,30,31,33 * claims 1,17,19 *;
 [X]WO2004091569  (CITRAMED LTD [IL], et al) [X] 1-3,5,6,9,10,14,18,20,21,23,30,33 * claims 12,13 * * page 2, line 27 - page 3, line 2 * * page 7, lines 25-30 * * page 27; example 14 *;
 [X]WO2007123790  (NOVAVAX INC [US], et al) [X] 1-3,5,6,9,10,14,18-21,23-25,28,30,31,33 * pages 27,28; example 1 * * pages 32,33; example 6 * * pages 37,38; example 10 * * figure 4 * * claims 1,16 * * page 16, line 31 - page 17, line 10 *;
 [X]WO9819545  (REINHARD MARK S [US], et al) [X] 1,2,5,6,9,10,14,18,20,21,23,30,33 * page 11, lines 10-12 * * claim 1 *;
 [X]US4137317  (PARIS GERALD Y, et al) [X] 1-3,5,6,9,10,14,18-21,23-26,28,30,31,33 * column 5, lines 21-30; claims 1,2 * * column 2, lines 51-53 *;
 [X]US5618840  (WRIGHT D CRAIG [US]) [X] 1-3,5,6,9,10,14,18,20,21,23-25,28,30,31,33 * column 2, lines 6-10 * * claims 1,4,9 *;
 [X]EP1537859  (PFIZER PROD INC [US]) [X] 1-3,5,6,9,10,14,18-25,27,28,30,31,33 * pages 18,19, paragraph 188 * * claims 9,10,21,22,30,31 *;
 [X]US2003113388  (PHAN DUNG [US]) [X] 1-3,5,6,9,10,14,18,20,21,23,30,33 * page 8, paragraph 85; claims 1,20 *;
 [X]US2004110667  (LINN EDWARDS E [US]) [X] 1-3,5,6,9,10,14,18,21,23-26,28-31,33 * claims 1,6,10,11 * * pages 4,5; examples 1-3; table 1 * * page 3, paragraph 25 * * page 4, paragraph 49 *;
 [X]JP2005179290  ;
 [X]JP2003252798  ;
 [PX]US2008107646  (CHUNG YIH-LIN [TW], et al) [PX] 1-4,6,7,9,12-14,17,18,20-25,27,30,31 * claims 1-3,5,7 * * page 3, paragraph 22 *;
 [PX]WO2008039472  (TARO PHARMACEUTICALS USA INC [US], et al) [PX] 1-3,5,6,9,10,14,18-25,27,28,30,31,33 * claims 1,4,10,23 * * page 1, paragraph 3 * * page 5, paragraph 23 * * page 9, paragraphs 47,48 *;
 [DA]US2003109582  (ZASLOFF MICHAEL A [US]) [DA] 1-7,9,12-14,17-33 * claims 10,11 * * page 2, paragraph 19 *;
 [DA]US2002076393  (FEHLBAUM PASCALE [US], et al) [DA] 1-7,9,12-14,17-33 * claims 16,17 * * page 1, paragraphs 7,9 *;
 [A]US2004116523  (POPOFF MICHEL YVAN [FR]) [A] 1-7,9,12-14,17-33 * page 4, paragraph 89 * * page 6, paragraphs 133-135; table II * * page 7, paragraph 148; table III * * page 8, paragraph 169 *;
 [X]  - SALOMAO K ET AL, "Chemical composition and microbicidal activity of extracts from Brazilian and Bulgarian propolis", LETTERS IN APPLIED MICROBIOLOGY 2004 GB, (2004), vol. 38, no. 2, ISSN 0266-8254, pages 87 - 92, XP002533389 [X] 1,2,4,5,9,12-14,17,18,23-25,28,30,31 * page 90; table 1 * * page 91, column L, paragraph 2 - column R; table 2 *

DOI:   http://dx.doi.org/10.1111/J.1472-765X.2003.01458.X
 [X]  - ABD EL-HADY FATEN K ET AL, "Effect of Egyptian Propolis on the susceptibility of LDL to oxidative modification and its antiviral activity with special emphasis on chemical composition", ZEITSCHRIFT FUER NATURFORSCHUNG SECTION C JOURNAL OF BIOSCIENCES, (200709), vol. 62, no. 9-10, ISSN 0939-5075, pages 645 - 655, XP008107420 [X] 1,2,4,9,12-14,17,18,23-25,28,30,31,33 * page 647, column L, paragraph 2 * * page 651; table 1 * * page 652, column R, paragraph L - page 653, column L, paragraph 1 * * pages 652,653; figures 6,7 *
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2005, no. 78, Database accession no. 2005-761733, XP002533394 & JP2005179290 A 20050707 (LION CORP) [X] 1-3,5,6,9,10,14,18,21,23,28,30,33 * abstract *
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2004, no. 25, Database accession no. 2004-259761, XP002533395 & JP2003252798 A 20030910 (SHISEIDO CO LTD) [X] 1-3,5,6,9,10,14,18,21,23,30,33 * abstract *
 [X]  - NARAYANA KOLLA J P ET AL, "Biological activity of phenylpropionic acid isolated from a terrestrial Streptomycetes", POLISH JOURNAL OF MICROBIOLOGY, (2007), vol. 56, no. 3, ISSN 1733-1331, pages 191 - 197, XP008107412 [X] 1,2,4,9,12-14,17-21,23,30 * page 192, column R, paragraph L - page 193, column L, paragraph 1 * * page 193, column L, paragraph 3 * * page 194, column R, paragraph L - page 195, column R, paragraph 1 * * page 195; table II * * page 106, column R, paragraph L *
 [X]  - BANKOVA V ET AL, "Chemical composition and antibacterial activity of Brazilian propolis", ZEITSCHRIFT FUER NATURFORSCHUNG SECTION C BIOSCIENCES, (1995), vol. 50, no. 3-4, pages 167 - 172, XP008107422 [X] 1,2,4,5,9,12-14,17,18,21,23-25,28,30 * page 168, column L, paragraph 2 * * page 169; tables I,II * * page 170, column L, paragraph 4 * * page 170, column R, paragraph 1 * * page 171, column L, paragraph L - column R, paragraph 2 *
 [X]  - FEASLEY, C. F. ET AL, "Effect of ortho substituents on the bacteriostatic properties of phenylacetic acid", JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION (1912-1977) ( 1941 ), 30, 41-4 CODEN: JPHAA3; ISSN: 0003-0465, (1941), XP008107417 [X] 1,2,4,9,12-14,17-20,23,28,30 * page 43; table II * * page 94, column L, paragraph 5 * * page 94, column R, paragraph 4 *
 [PX]  - DONG Q F ET AL, "Antifungal activity of crude extracts and fat-soluble constituents of Holotrichia diomphalia larvae", BIORESOURCE TECHNOLOGY, ELSEVIER, GB, vol. 99, no. 17, ISSN 0960-8524, (20081101), pages 8521 - 8523, (20080418), XP023182780 [PX] 1,2,4,5,9,12-14,17,18,21,23-25,28,30,31 * page 8522; table 1 * * page 8522, column R, paragraph 1 * * page 8522, column L, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/j.biortech.2008.03.010
 [DA]  - RABBANI G H ET AL, "Short-chain fatty acids improve clinical, pathologic, and microbiologic features of experimental shigellosis", JOURNAL OF INFECTIOUS DISEASES, (199902), vol. 179, no. 2, ISSN 0022-1899, pages 390 - 397, XP002523452 [DA] 1-7,9,12-14,17-33 * page 390, column R, paragraph 2 * * page 394; figure 2 * * page 395; figure 3 *

DOI:   http://dx.doi.org/10.1086/314584
 [A]  - SCHAUBER J ET AL, "Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: Relevance of signalling pathways", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, UK, (20030501), vol. 52, no. 5, ISSN 0017-5749, pages 735 - 741, XP008104565 [A] 1-4,6,9,14,17-19,21-23,28,30 * page 735, column R, paragraph 2 * * page 740, column R, paragraphs 4,5 *

DOI:   http://dx.doi.org/10.1136/gut.52.5.735
 [A]  - RAQIB RUBHANA ET AL, "Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC.; US, (20060613), vol. 103, no. 24, ISSN 0027-8424, pages 9178 - 9183, XP002495632 [A] 1-4,6,9,14,17-23,27,28,30 * abstract * * page 0182, column L, paragraph L *

DOI:   http://dx.doi.org/10.1073/pnas.0602888103
Examination   - JONAS STEINMANN, "Induction and regulation of CAMP gene expression", (2008), pages 1 - 38, URL: http://skemman.is/stream/get/1946/3275/10328/1/Jonas_Steinmann_fixed.pdf, (20121129), XP055046038
    - Induction of antimicrobial peptide gene expression in a bronchial epithelial cell line; Jonas Steinmann and Gudmundur Hrafn Gudmundsson
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.